Harvard-linked Sana Biotechnology will raise as much as $397m if it floats at the upper end and underwriters take up the greenshoe option.

The Tencent and Baidu-backed short-form video platform developer priced an offering valuing it at about $61bn at the top of its range.

Landos has filed to go public after a phase 2 trial of its Virginia Tech-invented IBD treatment produced favourable results this month.

Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.

Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.

Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.

The immunotherapy developer plans to go public in the US having raised $565m since being formed to develop assets of a defunct Oxford spinout.

The drama content producer, which counts iQiyi among its investors, has gone public in Hong Kong and seen its share price rise 84% on its first day of trading.

Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.

The JF Shea-backed social commerce marketplace priced its shares above the range in an offering valuing it at about $3bn.